Douglas C. Throckmorton, MD; Janet Woodcock, MD
Note: The authors are full-time employees of the U.S. government.
Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-2175.
Corresponding Author: Douglas C. Throckmorton, MD, U.S. Food and Drug Administration, Building 51, Room 6132, 10903 New Hampshire Avenue, Silver Spring, MD 20993; e-mail, Douglas.Throckmorton@fda.hhs.gov.
Current Author Addresses: Dr. Throckmorton: U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Building 51, Room 6132, Silver Spring, MD 20993.
Dr. Woodcock: U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Building 51, Room 6133, Silver Spring, MD 20993.
Throckmorton DC, Woodcock J. Combined Gabapentinoid and Opioid Use: The Consequences of Shifting Prescribing Trends. Ann Intern Med. ;169:727–728. doi: 10.7326/M18-2175
Download citation file:
Published: Ann Intern Med. 2018;169(10):727-728.
Published at www.annals.org on 21 August 2018
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use